

# Integrins $\alpha 2\beta 1$ and $\alpha 11\beta 1$ regulate the survival of mesenchymal stem cells on collagen I

C Popov<sup>1</sup>, T Radic<sup>1</sup>, F Haasters<sup>1</sup>, WC Prall<sup>1</sup>, A Aszodi<sup>1</sup>, D Gullberg<sup>2</sup>, M Schieker<sup>\*1</sup> and D Docheva<sup>1</sup>

Although mesenchymal stem cells (MSCs) are the natural source for bone regeneration, the exact mechanisms governing MSC crosstalk with collagen I have not yet been uncovered. Cell adhesion to collagen I is mostly mediated by three integrin receptors –  $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$  and  $\alpha 11\beta 1$ . Using human MSC (hMSC), we show that  $\alpha 11$  subunit exhibited the highest basal expression levels but on osteogenic stimulation, both  $\alpha 2$  and  $\alpha 11$  integrins were significantly upregulated. To elucidate the possible roles of collagen-binding integrins, we applied short hairpin RNA (shRNA)-mediated knockdown in hMSC and found that  $\alpha 2$  or  $\alpha 11$  deficiency, but not  $\alpha 1$ , results in a tremendous reduction of hMSC numbers owing to mitochondrial leakage accompanied by Bcl-2-associated X protein upregulation. In order to clarify the signaling conveyed by the collagen-binding integrins in hMSC, we analyzed the activation of focal adhesion kinase, extracellular signal-regulated protein kinase and serine/threonine protein kinase B (PKB/Akt) kinases and detected significantly reduced Akt phosphorylation only in  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC. Finally, experiments with hMSC from osteoporotic patients revealed a significant downregulation of  $\alpha 2$  integrin concomitant with an augmented mitochondrial permeability. In conclusion, our study describes for the first time that disturbance of  $\alpha 2\beta 1$ - or  $\alpha 11\beta 1$ -mediated interactions to collagen I results in the cell death of MSCs and urges for further investigations examining the impact of MSCs in bone conditions with abnormal collagen I.

Cell Death and Disease (2011) 2, e186; doi:10.1038/cddis.2011.71; published online 28 July 2011

Subject Category: Experimental Medicine

Mesenchymal stem cells (MSCs), derived from bone marrow, have been shown to differentiate into the osteoblast lineage *in vitro* as well as *in vivo*.<sup>1</sup> As a result of this ability, these cells are considered to be the main cellular players in the processes of bone regeneration and healing. In order to survive, amplify or differentiate into cells with a specialized function, MSC have to establish appropriate contacts with the extracellular matrix (ECM) in the bone marrow, which is mainly composed of collagen type I, IV and fibronectin.<sup>2</sup> One of the most important and ubiquitous receptor families mediating cell–ECM interactions is the integrin family. In vertebrates, there exist 18  $\alpha$ - and 8  $\beta$ -integrin subunits that can assemble into 24 different heterodimers.<sup>3,4</sup> Generally, the amount of  $\alpha$ -subunit determines the amount of receptor that will go to the cell surface as no free  $\alpha$ - or  $\beta$ -integrin can be present on the plasmalemma.<sup>5</sup> On the basis of the ligand-binding properties, the integrins can be grouped into subgroups as the collagen I-binding group consists of three receptors –  $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$  and  $\alpha 11\beta 1$ .<sup>5</sup>

Integrins do not only establish cell bonds with a range of ligands but also regulate cytoskeletal dynamics and initiate various signals that are essential for the regulation of cellular processes, such as cell adhesion, migration and

differentiation.<sup>6,7</sup> Integrin signaling is initiated at the focal adhesion sites, which are membrane-associated platforms consisting of clustered, ECM-bound integrins as well as various enzymes (e.g., focal adhesion kinase, FAK), cytoskeletal and adaptor proteins (e.g., paxillin, p130<sup>cas</sup>) in the cytoplasm. Integrin adhesion triggers ‘outside-in’ signaling, which frequently synergizes with growth factor-dependent cascades and activates downstream proteins such as extracellular signal-regulated protein kinases 1 and 2 (Erk1/2). Furthermore, integrin-mediated anchorage and signaling can also regulate cell survival processes and prevent cells entering anoikis, which is a special form of apoptosis triggered by inappropriate cell–ECM interactions.<sup>8,9</sup> For instance, the integrin-dependent adhesion of mammary and intestinal epithelial cells to the ECM is pivotal to avert anoikis through the activation of protein kinase B (PKB/Akt) survival pathway and the prevention of mitochondrial translocation of the proapoptotic protein Bcl-2-associated X protein (Bax).<sup>10–12</sup>

Although collagen I is one of the major proteins in the bone marrow, the precise roles of collagen-binding integrin receptors in human MSC (hMSC) behavior have not been investigated. In this study, we addressed the functions of  $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$  and  $\alpha 11\beta 1$  integrins in hMSC by applying short

<sup>1</sup>Department of Surgery, Ludwig-Maximilians-University (LMU), Nussbaumstr. 20, Munich, Germany and <sup>2</sup>Department of Biomedicine, University of Bergen, Jonas Lies vei 91, Bergen, Norway

\*Corresponding author: M Schieker, Department of Surgery, Ludwig-Maximilians-University (LMU), Nussbaumstr. 20, 80336 Munich, Germany.

Tel: 49-89-5160-7589; Fax: 49-89-5160-5482; E-mail: matthias.schieker@med.uni-muenchen.de

**Keywords:** mesenchymal stem cells; integrin receptor; apoptosis; osteogenic differentiation

**Abbreviations:** hMSC, human mesenchymal stem cell; shRNA, short hairpin RNA; Bax, Bcl-2-associated X protein; FAK, focal adhesion kinase; ERK, extracellular signal-regulated protein kinase; PKB/Akt, serine/threonine protein kinase B; con-shRNA, control shRNA; ECM, extracellular matrix; PLL, poly-L-lysine; BrdU, bromodeoxyuridine; hOB, human osteoblast; CD271, low-affinity nerve growth factor receptor; KD, knockdown; IFN $\beta$ , interferon  $\beta$ ; JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide; FAS, CD95 death receptor; hMSC OH, hMSC from older healthy donor; hMSC OP, hMSC from older osteoporotic donor; MNC, mononuclear cell; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SDS, sodium dodecyl sulfate; PD, population doubling; PAR, Alizarin Red

Received 06.5.11; revised 15.6.11; accepted 16.6.11; Edited by P Salomoni

hairpin RNA (shRNA)-mediated knockdown (KD) of the corresponding  $\alpha$ -subunits and performing all functional analysis on native human collagen type I. Our major finding was that the deficiency of  $\alpha 2$  or  $\alpha 11$  integrin in hMSC leads to initiation of cell apoptosis via Akt pathway, while the deficiency of  $\alpha 1$  integrin was entirely permissible for hMSC survival on collagen I. Furthermore,  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC completely failed to osteogenically differentiate because of the profound loss of cells throughout *in vitro* osteogenic stimulation (OS). Finally, a pilot investigation with hMSC derived from osteoporotic patients showed a significant downregulation of  $\alpha 2$  integrin in these cells. Taken together, our study reports for the first time that two of the collagen I-binding integrins,  $\alpha 2\beta 1$  and  $\alpha 11\beta 1$ , transmit essential and non-redundant signaling for hMSCs inhabiting collagen I-rich cell niches and that disturbance of the collagen I–integrin interactions results in stem cell death. Hence, we believe that our findings can open a novel way to interpret, understand and further investigate bone conditions in which the cell access to normal collagen I is affected.

## Results

**hMSC adhesion and proliferation are enhanced on collagen I and two of the collagen I-binding integrins are significantly upregulated in osteogenically differentiated hMSC.** First, we investigated the effect of collagen type I on hMSC adhesion and proliferation. For hMSC adhesion (Figure 1a) and proliferation analysis (Figure 1b), cells were cultivated on collagen I, fibronectin, laminin I, poly-L-lysine (PLL) or 5% milk/PBS (blotto). After 45 min, hMSC attachment to collagen I and fibronectin entered an adhesion plateau ( $92.6 \pm 7.2\%$  and  $98.1 \pm 2.9\%$ , respectively) whereas the cell adhesion to laminin I and PLL remained lower at all-time points (Figure 1a). Similar to the adhesion data, hMSC proliferation was significantly higher on collagen I and fibronectin demonstrated by bromodeoxyuridine (BrdU) incorporation assay (Figure 1b).

Next, we investigated the basal expression of  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 11$  and  $\beta 1$  subunits in hMSC and human osteoblasts (hOBs) by semi-quantitative PCR (Figure 1c). Both cell types were found to express all integrins. Quantitative PCR performed in hMSC revealed that, among the  $\alpha$ -subunits,  $\alpha 11$  had the strongest basal expression on collagen I and the  $\alpha 1$  mRNA levels were higher than  $\alpha 2$  (Figure 1d). In addition, we performed western blot analyses of hMSC, hOB and native bone tissue (Figure 1e). The signal for  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  was strong in cultured hMSC and hOB, while the freshly isolated low-affinity nerve growth factor receptor (CD271)-positive, non-cultured hMSC and human bone tissue revealed a weaker signal. However, we demonstrated for the first time the protein expression of the three collagen I-binding integrins in native hMSC, which were directly isolated and lysed from the bone marrow. Finally, we performed immunostaining for integrins  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  in hMSC cultured on collagen I (Figure 1f). The cells were positive for all subunits; however, the most robust focal adhesions were observed in the case of  $\alpha 11$ -specific staining.

In order to investigate if the collagen-binding integrin levels are altered during hMSC commitment into OB lineage, hMSC


were osteogenically stimulated. Figures 2a and b demonstrate the osteogenic differentiation, judged by Alizarin Red (AR) cytochemistry, and quantification, of three hMSC donors at day 21. The osteogenic differentiation was further validated by semi-quantitative PCR for osteoblast-specific genes namely, Osterix, osteocalcin and bone sialoprotein (Figure 2c). Quantitative RT-PCR analyses of  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  integrin expression revealed no changes for  $\alpha 1$  (Figure 2d), while  $\alpha 2$  and  $\alpha 11$  were significantly upregulated on hMSC OS (Figures 2e and f). The increase in  $\alpha 2$  and  $\alpha 11$  expression on protein level was confirmed by western blotting (Figure 2g).

Taken together, these findings demonstrate that first, collagen I promotes hMSC adhesion and proliferation; second, among the three collagen-binding integrins,  $\alpha 11$  has the most pronounced basal expression; and third, when hMSC differentiate toward OB,  $\alpha 2$  and  $\alpha 11$  integrins are significantly upregulated, thus suggesting an important role for hMSC functions on collagen I.

**Stable and efficient gene KD of  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  integrins in MSC from human bone marrow.** To examine the functional role of collagen-binding integrins, we applied small interference RNA technology. hMSC were stably transduced with control,  $\alpha 1$ ,  $\alpha 2$  or  $\alpha 11$  shRNAs and cells, which had no pro-virus integration were eliminated by antibiotic selection. RT-PCR and western blot analyses were used to estimate the degree of integrin KD (Figure 3). The overall efficiency of integrin KD was  $>85\%$  in all independent infections of each hMSC donor. Using the quantitative RT-PCR data, we analyzed if the downregulation of a particular integrin subunit leads to expression changes in the other two subunits (Figures 3b–d). We found that following integrin  $\alpha 1$  KD, the expression levels of  $\alpha 2$  and  $\alpha 11$  increased with  $1.7 \pm 0.1$  and  $3.7 \pm 0.5$ -fold, respectively. Similar changes occurred when integrin  $\alpha 2$  was diminished ( $\alpha 1$  with  $2.4 \pm 0.6$  and  $\alpha 11$  with  $2.1 \pm 0.5$ -fold increase). In contrast, the KD of integrin  $\alpha 11$  led only to  $1.7 \pm 0.1$ -fold increase in  $\alpha 1$  mRNA whereas the level of  $\alpha 2$  remained unchanged. These results were also apparent on protein levels (Figure 3e).

In conclusion, a very efficient and reproducible KD of  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  integrins was successfully established in hMSC. In addition, a compensatory upregulation among some of the integrin subunits was observed.

**hMSC deficient for  $\alpha 2$  or  $\alpha 11$  integrins exhibit a clear defect in adhesion, spreading and migration.** Subsequent to the establishment of integrin KD in hMSC, we investigated for changes in their cell attachment (Figure 4a), spreading (Supplementary Figures 2 and 4b) and migration on collagen I (Figures 4c–e). After 120 min, all control-shRNA (con-shRNA) and  $91.6 \pm 6.5\%$  of  $\alpha 1$ -shRNA hMSC were attached *versus* only  $79.1 \pm 2.5\%$  of  $\alpha 2$ -shRNA hMSC. The lowest cell adhesion was detected in  $\alpha 11$ -shRNA hMSC as these cells reached a maximal adhesion of just  $30.1 \pm 3\%$ . Con- and  $\alpha 1$ -shRNA cells required approximately 30 min to fully spread while  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC exhibited a significantly delayed spreading. More precisely, cells with  $\alpha 2$  and  $\alpha 11$  KD needed  $80.8 \pm 11.5$  min and  $61.7 \pm 6.3$  min to spread, respectively. Similar to the adhesion and spreading




**Figure 1** hMSC adhesion and proliferation on ECM proteins, and integrin expression profile. (a) Quantitative adhesion assay on collagen I, fibronectin, laminin I, PLL (poly-L-lysine) and blotto (5% milk/PBS). The highest hMSC adhesion was toward fibronectin and collagen I. The data represent two independent experiments. (b) Proliferation analysis. Cells were cultured for 24 h in the presence of 10 μM BrdU. The highest BrdU uptake was detected when hMSC were grown on collagen I. Three independent experiments, each consisting of triplicates, were performed ( $n = 9$ ;  $***P < 0.001$ ; one-way ANOVA). (c) Semi-quantitative PCR analysis of the basal expression of α1, α2, α11 and β1 integrin in hMSC and hOB. Shown is a representative experiment of three independent repeats. (d) Quantitative PCR analysis of collagen I-binding integrin expression revealed that α11 is the most strongly expressed integrin subunit in hMSC cultivated on collagen I. Data consist of three independent quantitative measurements with three donors ( $n = 9$ ;  $***P < 0.001$ ; one-way ANOVA). (e) Representative western blots for integrin α1, α2 and α11 in freshly isolated CD271-MNC and CD271 + hMSC, cultivated hMSC and hOB, and hBone protein extracts confirmed integrin protein expression *in vivo* and *in vitro*. (f) Immunofluorescent stainings of α1, α2 and α11 integrins of hMSC cultured on collagen I. Integrin α11 showed the most pronounced focal adhesions (indicated by arrows). The staining was reproduced twice, bar 50 μm and in the inset 20 μm

data, the α2- and α11-shRNA hMSC had also a migratory deficit. The average path con-shRNA cells took was  $171.3 \pm 31.3 \mu\text{m}$  with mean velocity of  $11.4 \pm 2.1 \mu\text{m/h}$  (Figure 4c). Similarly, α1-shRNA hMSC migrated to approximately 200 μm distances with  $13.9 \pm 0.4 \mu\text{m/h}$  of average speed. In comparison, the migration distance and velocity of α2- and α11-shRNA hMSC were significantly reduced to approximately 50% (Figures 4d and e). In conclusion, hMSC deficient for α2 and α11 integrin receptors exhibited a reduced adhesion, delayed spreading and lower migration velocity.

**KD of α2 or α11 integrin results in a dramatic loss of hMSC numbers and impaired osteogenic differentiation.** Throughout hMSC cultivation on collagen I, we detected a persistent decrease in cell numbers within the population of α2- and α11-shRNA-transduced cells (Figures 5a and b). In contrast, the con- and α1-shRNA hMSC continuously increased. In order to estimate the rate of cell regression, cell quantification was performed and the percentage of cell gain or loss between days 0 and 14 was determined (Figure 5b). At day 14, con- and α1-shRNA hMSC increased with  $55.8 \pm 16\%$  and  $76.3 \pm 42\%$ , whereas





**Figure 2** Expression changes in collagen I-binding integrins on hMSC commitment into osteoblasts. (a) hMSC were osteogenically stimulated for 21 days and the deposited calcified matrix was visualized by AR staining. (b) AR quantification. Experiments were performed with three donors ( $n=3$ ;  $***P<0.001$ ; unpaired *t*-test for each donor). (c) RT-PCR analysis of Osterix, osteocalcin (OCN) and bone sialoprotein (BSP) demonstrated the upregulation of bone-specific genes. Shown is a representative experiment of three independent repeats. Quantitative RT-PCR for integrin  $\alpha 1$  (d),  $\alpha 2$  (e) and  $\alpha 11$  (f) revealed that  $\alpha 2$  and  $\alpha 11$  integrins significantly upregulate on OS. Data shown are for all donors as three independent quantitative RT-PCR measurements were performed per donor, ( $n=9$ ;  $*P<0.05$ ;  $**P<0.01$ ;  $***P<0.001$ ; unpaired *t*-test for each donor). (g) Western blot analysis for  $\alpha 2$  and  $\alpha 11$  protein expression confirmed the previous findings. A representative experiment of two independent western blots is shown

$\alpha 2$ - and  $\alpha 11$ -shRNA significantly reduced to  $83.3 \pm 0.5\%$  and  $73.1 \pm 12.4\%$ , respectively of the original seeding density.

A viral infection or a presence of double-stranded RNA within the cells can lead to an activation of interferon (IFN) signaling, which then can result in IFN-mediated cell apoptosis.<sup>13</sup> In order to exclude that the observed reduction of  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC numbers is due to a triggered IFN pathway, we performed semi-quantitative PCR analyses of genes related to IFN pathway – OAS1, OAS2, retinoic acid-inducible gene 1 and IFN-induced protein with tetra-riptide repeats 1. hMSC stimulated with IFN $\beta$  were used as a positive control. As shown in Figure 5c, none of the tested genes showed distinctive upregulation in the shRNA-transduced hMSC.

Finally, we induced osteogenic differentiation of hMSC and observed that con- and  $\alpha 1$ -shRNA cells were able to differentiate into osteoblasts indicated by positive AR staining, whereas  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC did not deposit mineralized matrix shown by the lack of AR staining. Instead, during the stimulation period, a further significant regression in the cell numbers of both cell types was observed (Supplementary Figure 3).


Hence, we concluded that viral treatment and shRNA transduction in hMSC had no stimulatory effect on IFN

pathway and that only the gene KD of  $\alpha 2$  and  $\alpha 11$  integrins leads to a remarkable reduction of hMSC numbers during cultivation as well as OS.

#### hMSC deficient for $\alpha 2$ or $\alpha 11$ integrins exhibit a mitochondrial permeability, BAX upregulation and reduced activation of Akt.

The observed decline in  $\alpha 2$ - or  $\alpha 11$ -shRNA KD hMSC numbers suggested a survival defect on collagen I; therefore apoptosis was evaluated first by 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining (Figure 6). In viable cells, JC-1 aggregates in the intact mitochondria and produces red fluorescent signal (Figure 6a). In apoptotic cells, which have a mitochondrial leakage, JC-1 resides in the cytoplasm in a monomeric form and stains the cell cytoplasm in green (Figure 6b). Our results showed that con- and  $\alpha 1$ -shRNA hMSC populations consisted of mostly non-apoptotic cells (Figures 6c and d). In contrast,  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC, similarly to the positive control (hMSC treated with CD95 death receptor (FAS) antibody), were predominantly stained in green indicating mitochondrial leakage (Figures 6e and f).

Next, we carried out a western blot analysis for the pro-apoptotic factor Bax, which is responsible for mitochondrial



**Figure 3** Gene silencing of  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  integrins in hMSC. hMSC were transduced with  $\alpha 1$ -,  $\alpha 2$ - and  $\alpha 11$ -specific shRNA sequences as well as with con-shRNA. (a) Semi-quantitative PCR demonstrated a downregulation of the three targeted integrins. Data are representative of three independent experiments. Quantitative RT-PCR analysis for  $\alpha 1$  (b),  $\alpha 2$  (c) and  $\alpha 11$  (d) integrins in shRNA-transduced hMSC. The analysis showed a significant and reproducible integrin silencing in hMSC. Additionally, a compensatory upregulation was evident between the three  $\alpha$ -subunits. Data consist of quantitative RT-PCR measurements from three independent infections ( $n=3$ ; \* $P<0.05$ ; \*\* $P<0.01$ ; \*\*\* $P<0.001$ ; ANOVA tested *versus* con-shRNA). (e) Confirmation of the integrin  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  KD on protein level. Shown is a representative experiment from two independent western blots of all donors

membrane permeabilization.<sup>14</sup> A significantly elevated Bax expression was observed only in  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC (Figure 7a).

Finally, we analyzed the activation of the integrin downstream targets FAK (Figure 7b), ERK (Figure 7c) and Akt (Figure 7d) using phospho-specific antibodies. The pFAK levels were significantly reduced by approximately 50% in all integrin-deficient hMSC, whereas a slight reduction of pERK and almost a complete loss of pAkt were detected only in  $\alpha 2$ - and  $\alpha 11$ -KD hMSC. Thus, we concluded that the hMSC shortfall observed after  $\alpha 2$  or  $\alpha 11$  KD is the consequence of cell apoptosis because of the lack of adhesion-dependent activation of the major survival effector – Akt.


**A significant downregulation of  $\alpha 2$  integrin revealed in hMSC derived from osteoporotic patients.** To investigate a hypothetical relationship between osteoporosis and integrin dysregulation, a pilot study with hMSC derived from older healthy (hMSC OH,  $n = 3$ ) and older osteoporotic donors (hMSC OP,  $n = 6$ ) (Supplementary Table 1) was performed. We analyzed the expression profile of the collagen-binding integrins in these cells and compared it with that of hMSC from the younger healthy donors. Hence, an intriguing trend was found: first,  $\alpha 2$  and  $\alpha 11$  integrins were upregulated during aging (Figure 8a) and second, no changes were detected in  $\alpha 1$  expression in hMSC OP whereas  $\alpha 11$  was slightly upregulated in hMSC OP (Figure 8b). Most strikingly,

a significant, 17-fold downregulation of  $\alpha 2$  was detected in hMSC OP (Figure 8b) as well as a notable number of cells exhibited a mitochondrial leakage (Figure 8c) in comparison with hMSC OH (Figure 8b).

### Discussion

In this study, we investigated the role of the collagen I-binding integrins,  $\alpha 1\beta$ ,  $\alpha 2\beta$  and  $\alpha 11\beta$ , in human, bone marrow-derived MSC. We applied a stable, shRNA-based integrin silencing and observed significant changes only in the behavior of hMSC deficient for  $\alpha 2$  or  $\alpha 11$  integrin subunits. The major cellular changes comprises (Figure 9): (i) reduced adhesion, spreading and motility on collagen I; (ii) increased apoptosis associated with mitochondrial leakage and Bax upregulation; and (iii) affected integrin-mediated signaling to Akt, FAK and ERK.

Owing to the high rates of hMSC adhesion and proliferation on collagen I, we first examined the expression levels of the collagen I-binding integrins in hMSC cultivate on collagen I and found that among the three different collagen I-binding  $\alpha$ -subunits,  $\alpha 11$  integrin had the highest basal expression. Our study also reported for the first time the *in vivo* expression of the three  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  integrins by analyzing freshly isolated, non-cultured hMSC. Furthermore, we clearly demonstrated that  $\alpha 2$  and  $\alpha 11$  integrins, but not  $\alpha 1$ , were significantly upregulated on OS of hMSC. Forster *et al.*<sup>15</sup> have




**Figure 4** Investigation of adhesion, spreading and migration of integrin-deficient hMSC on collagen I. (a) Quantitative adhesion assay demonstrated that  $\alpha 2$ - and  $\alpha 11$ -shRNA-transduced hMSC have reduced attachment to collagen I in comparison with  $\alpha 1$ - and con-shRNA hMSC. Data consist of two independent infections; experiments were performed in triplicate. (b) Time lapse analysis of cells spreading on collagen I showed significant delay of hMSC deficient for  $\alpha 2$  or  $\alpha 11$  subunits. (c) Shown is a panel of images representative of the migration distance taken by a single control or shRNA-transduced hMSC. Cell tracks are indicated with black arrows. Quantification of migration distance (d) and velocity (e) revealed significantly lower motility of  $\alpha 2$ - and  $\alpha 11$ -shRNA hMSC. Time-lapse analysis was performed after two independent infections. Data in b, d and e are representative of three independent movies as a total of 30 cells per type were evaluated ( $n = 3$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$ ; ANOVA tested *versus* con-shRNA)

previously demonstrated by quantitative proteomic analysis that the amount of collagen I, as well as  $\alpha 2$  and  $\alpha 11$  integrins, increases during hMSC osteogenic differentiation. Hence, we suggest that the elevation of  $\alpha 2$  and  $\alpha 11$  might be a

consequence of the changes in collagen I production in the differentiating cells.

To investigate the role of these three receptors in hMSC, we next performed a loss-of-function analysis. After the




**Figure 5** Cell regression of hMSC after integrin KD and investigation of IFN pathway-related genes. (a) Subsequent to the antibiotic selection, cells were pictured every 24 h for a period of 14 days. Shown are representative images at day 0 and 14. (b) hMSC deficient for  $\alpha 2$  or  $\alpha 11$  integrin decrease in number during cultivation *in vitro*. In contrast,  $\alpha 1$ -shRNA and con-shRNA hMSC were able to expand. In the text inset, the total cell gain or cell loss between day 0 and 14 is shown in percentage. The experiment was performed in duplicates with two donors as the total cell number in 1.1 cm<sup>2</sup> area was automatically counted by ImageJ software. (c) RT-PCR was performed for OAS1, OAS2, retinoic acid-inducible gene I (RIG-I) and IFN-induced protein with tetratricopeptide repeats 1 (IFIT1), genes involved in IFN-related cell death. The PCR results showed that none of the tested genes were upregulated after viral transduction of shRNA. Shown is a representative experiment of three independent infections. Positive control: hMSC treated with  $2 \times 10^3$  U/ml IFN $\beta$  for 72 h

accomplishment of almost complete silencing of each integrin subunit, we observed that only hMSC deficient for  $\alpha 2$  or  $\alpha 11$  integrins exhibited adhesion, spreading and migration deficits on collagen I while  $\alpha 1$ -deficient cells behaved similarly to control hMSC. Changes in adhesion and migration efficacy after the loss of collagen I-binding integrins have been described only in mouse cells derived from integrin knockout models.<sup>16–19</sup> However, the phenotype of bone marrow-derived MSC has not been investigated so far. Using  $\alpha 2$ -knockout keratinocytes and dermal fibroblasts, it was shown that  $\alpha 2$  integrin regulates the cell attachment and migration on collagen I, whereas adhesion to collagen IV and laminin I is permissive.<sup>16,17</sup> Popova *et al.*<sup>18,19</sup> reported a positive effect of integrin  $\alpha 11$  on embryonic fibroblast adhesion and spreading on collagen I. In contrast, the investigators observed that this cell type was actually able to migrate faster on various collagens when  $\alpha 11$  was missing.<sup>18</sup> The reported discrepancy in the migratory behavior of integrin-deficient cells could be explained with the notion that collagen-binding integrins might exert different effects on cell adhesion and migration depending on the cell type or on the availability of other compensatory integrin subunits. In our

study with human MSC, we observed that in the absence of  $\alpha 2$  integrin,  $\alpha 1$  and  $\alpha 11$  subunits were significantly upregulated, while only a slight increase in  $\alpha 1$  was detected subsequent to  $\alpha 11$  KD. Hence, we suggest that the adhesion deficit of  $\alpha 2$ -deficient cells was not as severe as that of  $\alpha 11$  because one or both remaining integrins could have a compensatory role.

Integrins have been implicated also in the control of cell differentiation and survival. Salaszyk *et al.*<sup>20,21</sup> demonstrated that FAK and ERK signaling regulate the osteogenic differentiation of hMSC on collagen I, however, in these studies the upstream pathway or an integrin involvement was not examined. Integrins are also known to trigger pro-survival signals when cells interact with ECM proteins, but when such contacts are disturbed, integrins can as well initiate cell death.<sup>22</sup> It has been reported in human lung fibroblasts that the disruption of ECM–integrin  $\beta 1$  interactions leads to reduced cell survival because of negatively affected FAK and Akt signaling.<sup>23</sup> Several studies have also coupled integrin signaling with Bcl-2/Bax-dependent apoptotic machinery in keratinocytes<sup>24</sup> and calvaria-derived fibroblasts.<sup>25</sup> It has been shown in rat MSC<sup>26</sup> that transfection of integrin-linked kinase, a downstream effector of  $\beta 1$  integrin, results in






**Figure 6** Investigation of the mitochondrial integrity of integrin-deficient hMSC. Representative microphotographs of hMSC cultivated on collagen I and stained with JC-1. JC-1 dye aggregates and emits red color in cells with intact mitochondria such as non-treated hMSC (a), con- (c) and  $\alpha 1$ -shRNA hMSC (d) whereas apoptotic cells are labeled in green as in the positive control – hMSC treated with 1  $\mu\text{g/ml}$  FAS antibody (b). hMSC with  $\alpha 2$  (e) or  $\alpha 11$  (f) KD are labeled in green indicating that their mitochondria are permeabilized. Cytochemistry was performed twice independently with two donors

reduction of the pro-apoptotic Bax levels and thus, assists the MSC survival in hypoxic conditions. However, our study is the first one to demonstrate that the loss of collagen I–integrin interactions triggers stem cell death; using hMSC, we showed that the downregulation of  $\alpha 2$  or  $\alpha 11$  integrin, but not  $\alpha 1$ , leads to induction of apoptosis. As no activation of the IFN pathway was detected, we concluded that the observed cell apoptosis is indeed specific to the KD of  $\alpha 2$  or  $\alpha 11$  integrin. These cell populations were unable to expand *in vitro*. Moreover, as a predominant fraction of adherent cells exhibited mitochondrial leakage and a significant elevation of Bax protein levels, we suggest that the cell apoptosis was initiated before cell detachment. We also detected a reduction in the phosphorylation of FAK and ERK in the three integrin KDs. However, the most pronounced reduction of pERK was found in the  $\alpha 2$ - or  $\alpha 11$ -deficient hMSC. Furthermore, both cell populations showed a dramatic reduction of pAkt levels. Finally, as  $\alpha 2$ -deficient cells underwent cell death, despite the

upregulation of  $\alpha 1$  and  $\alpha 11$ , we propose that each integrin triggers a specific, non-dismissive downstream signaling cascade. Further studies, however, are required to dissect the exact signaling pathways mastered by  $\alpha 2$  and  $\alpha 11$  integrins in hMSC and other cell types.

A recent study reported that  $\alpha 11$  integrin deficiency in mice results in disorganized periodontal ligament, halted incisor eruption and tooth-dependent dwarfism.<sup>19</sup> The investigators identified a number of apoptotic cells in the periodontal ligaments. This tissue is highly enriched with collagen I and  $\alpha 11\beta 1$  integrin is the only collagen receptor. Interestingly, when fed with soft food, the  $\alpha 11$  knockouts only partially overcame their growth retardation. We propose that this tooth-independent growth defect might be linked to insufficient skeletal development because of MSC deficit. In contrast to  $\alpha 11$ , integrin  $\alpha 1$  and  $\alpha 2$  knockout mice show no gross developmental abnormalities.<sup>27,28</sup> Taken together, the relatively mild phenotypes of  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  mutant mice






**Figure 7** Investigation of cell apoptosis. (a) Western blot analysis for Bax, a pro-apoptotic marker, revealed a significant elevation of this protein in  $\alpha 2$ - or  $\alpha 11$ -deficient hMSC ( $n = 3$ ;  $**P < 0.01$ ; ANOVA tested versus con-shRNA). Quantification of three independent western blot experiments is shown. (b–d) Representative western blots of phosphorylated and total FAK, ERK and Akt in control and integrin KD hMSC. pFAK was significantly reduced in all integrin-deficient hMSC whereas a slight reduction of pERK and almost a complete loss of pAkt was detected only in  $\alpha 2$ - or  $\alpha 11$ -shRNA hMSC. Quantification analyses were performed from two independent infections and western blotting ( $n = 2$ ,  $*P < 0.05$ ;  $**P < 0.01$ ;  $***P < 0.001$ ; ANOVA tested versus con-shRNA)

suggest that, under normal physiological conditions, there is a functional redundancy between the individual collagen receptors. However, in certain tissues or cell types, or under disease-like conditions, these receptors might execute indispensable functions. Therefore, our study urges further

investigation of the bone marrow niche of the single or double knockout mice as well as on their involvement in experimental models challenging bone development or healing.

Another possible field for further investigation includes bone conditions associated with collagen I abnormalities such as



**Figure 8** Pilot investigation of the mRNA levels of collagen I-binding integrins in hMSC derived from younger healthy ( $n = 3$ ), older healthy (hMSC OH,  $n = 3$ ) and older osteoporotic patients (hMSC OP,  $n = 6$ ). For donor information refer to Supplementary Table 1. (a) Quantitative RT-PCR showed an upregulation of  $\alpha 2$  and  $\alpha 11$  integrins during aging (young hMSC versus hMSC OH;  $n = 9$ ;  $*P < 0.05$ ;  $**P < 0.01$ ; unpaired *t*-test for each  $\alpha$ -integrin subunit). (b) Comparison between hMSC OH and hMSC OP revealed that integrin  $\alpha 2$  was significantly downregulated in hMSC OP ( $n = 15$ ;  $**P < 0.01$ ; unpaired *t*-test for each  $\alpha$ -integrin subunit). (c) JC-1 staining demonstrated in hMSC OP a prominent number of cells with mitochondrial permeabilization (green-labeled cells) in contrast to control hMSC, which had mostly intact mitochondria (red-labeled cells). Photomicrographs represent three different hMSC OP donors


osteogenesis imperfecta and osteoporosis. A recent study has reported mutations causing osteogenesis imperfecta in type I collagen, which are located in the binding sites for integrins and proteoglycans.<sup>29</sup> Another study found in patients with specific collagen I polymorphism that the collagen I  $\alpha 1$  and  $\alpha 2$  chains were made in an aberrant ratio and suggested that this is relevant for the onset of osteoporosis.<sup>30</sup> Furthermore, it has been shown that the total amount of collagen I protein is decreased in hMSC derived from osteoporotic patients<sup>31</sup> and that osteoblasts isolated from patients with osteoporotic or osteoarthritic condition have reduced attachment and spreading as well as decreased FAK activation.<sup>32</sup> However, several other studies have found no dramatic changes in the hMSC proliferative and differentiation capacity from osteoporotic patients.<sup>33,34</sup> One possible explanation for this discrepancy is the variability in hMSC preparation and validation. On the basis of our results and the literature, we now speculate that in such conditions, one additional factor might be that the MSC population is being gradually exhausted *in vivo* because of loss of ECM interactions and subsequent cell death. Therefore, we performed a pilot analysis with hMSC derived from osteoporosis-suffering patients and found that, in comparison with hMSC from healthy old patients, the osteoporotic cells have significantly reduced mRNA levels of  $\alpha 2$  integrin. Importantly, further experiments involving higher

number of patients will be necessary to clarify what role integrin expression and signaling undertake in bone diseases. Such studies are currently ongoing.

In conclusion, our study contains the first cellular and molecular analysis demonstrating the role of collagen I-binding integrins in the survival of MSCs in collagen I-rich environment and calls for future investigations examining the impact of MSCs in bone conditions with abnormal collagen I.

#### Materials and Methods

**Human cells and cell culture.** The summary of hMSC donors used in this study is shown in Supplementary Table 1. hMSC were purchased from Lonza (Basel, Switzerland) or were isolated from bone marrow by ficoll gradient centrifugation (the procedure was approved by the LMU ethical commission, grant 311–04). The hMSC characteristics were verified by the producer or by us according to Dominici *et al.*<sup>35</sup> Briefly, hMSC were proven by FACS to be positive (>98%) for the MSC-related markers, 5'-nucleotidase, GPI-linked glycoprotein and endoglin, and negative for the hematopoietic-related markers, monocytes/macrophages receptor, hematopoietic progenitor marker and protein tyrosine phosphatase receptor type C and by two-lineage differentiation to be multipotent (data not shown). hMSC were cultured in MEM Alpha GlutaMAX medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (Sigma, Taufkirchen, Germany) and were grown on plastic or 10  $\mu$ g/ml native human collagen I-coated surfaces (BD Biosciences, San Jose, CA, USA). hMSC at passages 5–9 were used in the experiments. hOBs were purchased from PromoCell (Heidelberg, Germany) and maintained in OB-specific growth medium (PromoCell). Cells were maintained at 60–80% confluence in T-75 culture flasks, at 37 °C/5%



**Figure 9** Schematic model summarizing the cell phenotype of human MSC deficient for integrin  $\alpha 2$  or  $\alpha 11$ . Integrins are heterodimeric receptors (white and blue forms) having central roles in establishment of cell to extracellular matrix interactions (e.g., collagen type I, pink shape) and in regulation of crucial cell processes (arrows) by engaging various integrin-, membrane-, actin- and signaling-associated proteins (multi-color dots). As the amount of  $\alpha$ -subunit determines the amount of receptor present on the plasmalemma, we applied here a lentiviral delivery of  $\alpha$ -subunit-specific shRNA in hMSC. Thereby, highly efficient and stable KD of integrin  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  was achieved (represented by the translucent  $\alpha$ -subunit). Our functional analyses showed that only the deficiency of  $\alpha 2$  or  $\alpha 11$  integrin leads to significant changes in hMSC behavior on collagen I (red arrows). Most importantly, hMSC maintenance was affected as these cells displayed features typical for cell apoptosis. Taken together, this study reports for the first time that disturbance of collagen I-integrin interactions results in the cell death of MSCs. The image is adapted from Docheva *et al.*<sup>7</sup>

CO<sub>2</sub>. CD271-negative mononuclear cells (MNCs) and CD271-positive hMSC were isolated with a CD271 MicroBead kit (Miltenyi Biotec, Bergish Gladbach, Germany) from three human bone marrow MNC fractions (Cat. No. 2M-125C) purchased from Lonza and immediately after the cell separation the freshly isolated cells were lysed for protein analysis.

**shRNA cloning, lentiviral production and infection of hMSC.** shRNA oligonucleotides were designed with Invitrogen's BLOCK-iT RNAi Designer (Invitrogen) against the human integrin  $\alpha 1$ ,  $\alpha 2$  and  $\alpha 11$  and  $\beta$ -galactosidase genes (Supplementary Table 2). Double-stranded oligonucleotides were annealed and ligated into the pENTR/U6 vector according to the manufacturer's instructions (Invitrogen). The shRNA constructs were transferred to the final pLenti4/BlockIT-DEST expression vector by recombination using LR Clonase (Invitrogen) and were validated by sequencing. The final plasmids were prepared with EndoFree Plasmid Maxi Kit (Qiagen, Hilden, Germany). For viral production and cell infection, Invitrogen's ViraPower lentiviral system was used. The pLenti4/BlockIT-U6-shRNA plasmid was transfected into 293FT cells and viral supernatant was collected after 48 h. hMSC were incubated with the virus-containing supernatant for 24 h in the presence of 8  $\mu$ g/ml polybrene (Sigma) and were selected with 50  $\mu$ g/ml Zeocin (Invitrogen) for 10 days. As the three different donor-derived cells represented equivalent hMSC populations (Supplementary Figure 1), we designated hMSC XI as the main donor. hMSC XI was infected independently three times and used in all experiments. The additional two donors, hMSC XIII and hMSC XV, were infected once and were used only in the major experiments to confirm that the observed phenotype is not donor-specific.

**Semi-quantitative and real-time PCR.** Total RNA was extracted with RNeasy Mini Kit (Qiagen). For cDNA synthesis, 1  $\mu$ g total RNA and AMV First-

Strand cDNA Synthesis Kit (Invitrogen) were used. RT-PCR was performed with Taq DNA Polymerase (Invitrogen) in MGRsearch instrument (Bio-Rad, Munich, Germany). Primer pairs and PCR conditions are listed in Supplementary Table 3. For quantitative RT-PCR, LightCycler Fast Start DNA Master SYBR Green kit (Roche, Munich, Germany) and primer kits for  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 11$  and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Search-LC, Heidelberg, Germany) were used. The quantitative RT-PCR was performed in LightCycler1.5 instrument (Roche) equipped with LightCycler3.5.3 software. Crossing points for each sample were determined by the second derivative maximum method and relative quantification was performed using the comparative  $\Delta\Delta$ Ct method according to the manufacturer's protocol. The relative gene expression was calculated as a ratio to GAPDH. All PCR results have been reproduced minimum three times. For PCR analysis of IFN-related gene expression, a positive control was prepared by incubating hMSC with  $2 \times 10^3$  U/ml IFN $\beta$  (Cat. No. CYT-26766, Dianova, Germany) for 72 h at 37 °C as demonstrated in Croitoru-Lamoury *et al.*<sup>36</sup>

**Western blot analysis.** Adherent cells were directly lysed in 1x Laemmli buffer (200 mM Tris-HCl pH 6.8, 40% glycerol, 10% sodium dodecyl sulfate (SDS), 30% 2-mercaptoethanol, 0.02% bromphenolblue and 0.2M dithiothreitol). The lysates were homogenized, denatured at 99 °C for 5 min and centrifuged at 4 °C for 10 min. Equal volumes of the protein lysates were loaded on 8% or 15% SDS-PAGE gels and transferred onto polyvinylidene fluoride membranes. For blocking, 5% skim milk (Merck, Darmstadt, Germany) in Tris-buffered saline buffer (0.05% Tween20) was used. The following primary anti-human antibodies were applied: integrins  $\alpha 1$  and  $\alpha 11$  (both R&D Systems, Minneapolis, MN, USA), integrin  $\alpha 2$  (BD Biosciences), Bax (Biolegend, San Diego, CA, USA), phospho-FAK (Invitrogen), total FAK, total and phospho-ERK1/2, and total and phospho-Akt (all Cell Signaling, Danvers, MA, USA). In the western blot analysis,  $\beta$ -actin (Santa Cruz Biotechnology, Santa Cruz,



CA, USA) was used as a loading control allowing for a simultaneous detection with the integrins on the same protein membrane. The antibodies were diluted in the blocking solution and incubated overnight at 4 °C. Secondary horseradish peroxidase-conjugated antibodies (Rockland, Gilbertsville, PA, USA or Santa Cruz) were applied for 1 h at room temperature. Electrochemiluminescence solution (GE Healthcare, Waukesha, WI, USA) and Lumi-detection films (Roche) were used for protein visualization. Band intensities were quantified with ImageProPlus4 software program (Media Cybernetics, Bethesda, MA, USA).

**Immunocytochemistry and cytochemistry.** hMSC were cultured on 30 µg/ml collagen I-coated glass slides (BD Biosciences) for 48 h. The cells were fixed with methanol or acetone/methanol, treated with Image-iT FX signal enhancer (Invitrogen) and blocked with 10% BSA. Primary antibodies against integrins α1 (R&D Systems), α2 (AbD Serotec, Oxford, UK) and α11<sup>37</sup> were applied overnight at 4 °C. Next, secondary Alexa Fluor 488-conjugated antibodies and 4',6-diamidino-2-phenylindole were used (all Invitrogen). For apoptosis analysis, the fluorescent JC-1 dye (Invitrogen) was implicated. shRNA-transduced hMSC (2 × 10<sup>3</sup> cells/cm<sup>2</sup>) were cultured on collagen I-coated glass slides for 24 h. On the basis of Kennea et al.,<sup>38</sup> to create a positive control for apoptosis, hMSC were treated with 1 µg/ml FAS antibody (BD Biosciences) for 2 h at 37 °C, followed by overnight incubation with 1 µg/ml donkey anti-mouse IgG (Santa Cruz). Next, the cells were incubated with 3 µg/ml JC-1 and 1 µg/ml 2,5'-Bi-1H-benzimidazole (both Invitrogen) solved in complete growth medium for 30 min at 37 °C/5% CO<sub>2</sub>. Photomicrographs were taken with AxioCam MRm camera (Carl Zeiss, Jena, Germany) on Axioskope 2 or Axiovert100 microscope (Carl Zeiss). Staining procedures were reproduced at least twice with hMSC XI and hMSC XIII.

**Proliferation analyses.** Long-term cell growth was examined by calculating hMSC cumulative population doubling (PD) and PD time according to Docheva et al.<sup>39</sup> S-phase analysis was performed with the Cell Proliferation ELISA, BrdU (colorimetric) kit (Roche) as described in Böker et al.<sup>40</sup> Briefly, 96-well dishes were coated with 10 µg/ml collagen I (BD Biosciences), fibronectin, laminin I and PLL (all R&D Systems) and seeded with 3 × 10<sup>3</sup> hMSC per well. After 12 h, media supplemented with 10 µM BrdU was added. BrdU incorporation was measured after 24 h using microplate reader (Microtek, Overat, Germany) at 450 nm with 690 nm reference wavelength. Three independent experiments were performed in triplicate. For assessment of cell numbers after shRNA transduction, hMSC XI and XV were plated in six-well dishes and microscopically photographed every 24 h for a period of 14 days. Then, two different areas per well (each 1.1 cm<sup>2</sup>) were used for automated cell counting by ImageJ software program (<http://rsb.info.nih.gov/ij/>).

**Adhesion assay.** Cell adhesion assay was performed as described in Docheva et al.<sup>39</sup> In brief, 96-well plates were coated with 10 µg/ml collagen I, fibronectin, laminin I and blocked with 5% milk/PBS (blotto). hMSC were plated in triplicate (3 × 10<sup>3</sup> cells per well) and incubated for various time periods (15–120 min) at 37 °C, then non-adherent cells were removed by PBS washing. Cell adhesion was colorimetrically estimated using p-nitrophenyl N-acetyl-beta-D-glucosaminide (Sigma-Aldrich, Munich, Germany) as a substrate. Absorbance was measured at 405 nm on microtitre-plate reader (Microtek). The percentage of adherent cells was calculated to a maximal reference (suspension of 3 × 10<sup>3</sup> cells). Two independent experiments were performed.

**Live cell imaging.** Time lapse experiments were performed with an automated Axiovert100 inverted microscope system (Carl Zeiss) equipped with controlled biochamber (Pecon, Erbach, Germany). hMSC (2 × 10<sup>4</sup> cells per well) were plated on collagen I-coated six-well dishes. For spreading analysis, cells were imaged immediately after plating with 20 frames/h for 3 h using 20 objective and AxioCam MRm camera (Carl Zeiss). For migration analysis, cells were imaged 3 h after plating for 18 h with 4 frames/h. Three independent movies were produced and approximately 30 cells per type were evaluated. hMSC XI, from two independent viral infections, were used for the time lapse-based experiments. The obtained data were processed with AxioVision LE (Carl Zeiss) and ImageJ software programs.

**Osteogenic differentiation.** OS was performed as described previously in Böker et al.<sup>40</sup> Briefly, hMSC were plated in six-well dishes in a density of 3.5 × 10<sup>3</sup> cells/cm<sup>2</sup>. Osteogenic media was applied for 21 days and was changed twice weekly. The osteogenic differentiation was evaluated by AR staining, which visualizes calcium-rich deposits produced by the cells. AR staining and quantification were performed with Osteogenic Quantification kit (Millipore,

Billerica, MA, USA) according to the manufacturer's instructions. First, pictures were taken on Axiovert100 microscope with AxioCam ICc3 color camera (Carl Zeiss) and next, AR was extracted with 10% acetic acid and neutralized with 10% NH<sub>4</sub>OH. Optical density measurements were taken at 405 nm on microtitre-plate reader (Microtek). The AR amount was calculated against an AR standard curve. The experiment was repeated three times.

**Statistics.** Statistical evaluation was performed using the GraphPrism software (GraphPad, La Jolla, CA, USA). All quantitative data were acquired from two or three independent experiments, each performed with duplicates or triplicates. Graphs and bar charts show mean values and S.D. Unpaired *t*-test was used for two group analysis and Dunnett's one-way ANOVA was applied for multi group statistical testing. A *P*-value < 0.05 was considered statistically significant.

### Conflict of Interest

The authors declare no conflict of interest.

**Acknowledgements.** DD, CP and MS acknowledge the financial support of the German Research Foundation (DFG Grant: DO 1414/1-1). Parts of this work contributed to the PhD thesis of CP at the LMU Munich. DD and MS acknowledge Professor W Mutschler (Head of Surgery Clinic, LMU) for his constant support of the research laboratory and Dr. Katie Bungartz for carefully reading the paper.

- Kassem M, Kristiansen M, Abdallah BM. Mesenchymal stem cells: cell biology and potential use in therapy. *Basic Clin Pharmacol Toxicol* 2004; **95**: 209–214.
- Nilsson SK, Debatis ME, Dooner MS, Madri JA, Quesenberry PJ, Becker PS. Immunofluorescence characterization of key extracellular matrix proteins in murine bone marrow *in situ*. *J Histochem Cytochem* 1998; **46**: 371–377.
- Stuiver I, O'Toole TE. Regulation of integrin function and cellular adhesion. *Stem Cells* 1995; **13**: 250–262.
- Wiesner S, Legate KR, Fassler R. Integrin-actin interactions. *Cell Mol Life Sci* 2005; **62**: 1081–1099.
- Barczyk M, Carracedo S, Gullberg D. Integrins. *Cell Tissue Res* 2010; **339**: 269–280.
- Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell* 2002; **110**: 673–687.
- Docheva D, Popov C, Mutschler W, Schieker M. Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. *J Cell Mol Med* 2007; **11**: 21–38.
- Gilmore AP, Anokis. *Cell Death Differ* 2005; **12**: 1473–1477.
- Stupack DG. Integrins as a distinct subtype of dependence receptors. *Cell Death Differ* 2005; **12**: 1021–1030.
- Farrelly N, Lee YJ, Oliver J, Dive C, Streuli CH. Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. *J Cell Biol* 1999; **144**: 1337–1348.
- Bouchard V, Harnois C, Demers MJ, Thibodeau S, Laquerre V, Gauthier R et al. B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. *Apoptosis* 2008; **13**: 531–542.
- Benoit YD, Larrivee JF, Groulx JF, Stankova J, Vachon PH, Beaulieu JF. Integrin alpha8beta1 confers anoikis susceptibility to human intestinal epithelial crypt cells. *Biochem Biophys Res Commun* 2010; **399**: 434–439.
- Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. *Apoptosis* 2003; **8**: 237–249.
- Autret A, Martin SJ. Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. *Mol Cell* 2009; **36**: 355–363.
- Foster LJ, Zeemann PA, Li C, Mann M, Jensen ON, Kassem M. Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. *Stem Cells* 2005; **23**: 1367–1377.
- Zhang ZG, Bothe I, Hirche F, Zweers M, Gullberg D, Pfitzer G et al. Interactions of primary fibroblasts and keratinocytes with extracellular matrix proteins: contribution of alpha2beta1 integrin. *J Cell Sci* 2006; **119**: 1886–1895.
- Grenache DG, Zhang Z, Wells LE, Santoro SA, Davidson JM, Zutter MM. Wound healing in the alpha2beta1 integrin-deficient mouse: altered keratinocyte biology and dysregulated matrix metalloproteinase expression. *J Invest Dermatol* 2007; **127**: 455–466.
- Popova SN, Rodriguez-Sanchez B, Liden A, Betsholtz C, Van Den BT, Gullberg D. The mesenchymal alpha11beta1 integrin attenuates PDGF-BB-stimulated chemotaxis of embryonic fibroblasts on collagens. *Dev Biol* 2004; **270**: 427–442.
- Popova SN, Barczyk M, Tiger CF, Beertsen W, Zigrino P, Aszodi A et al. Alpha11 beta1 integrin-dependent regulation of periodontal ligament function in the erupting mouse incisor. *Mol Cell Biol* 2007; **27**: 4306–4316.

20. Salaszyk RM, Klees RF, Hughlock MK, Plopper GE. ERK signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells on collagen I and vitronectin. *Cell Commun Adhes* 2004; **11**: 137–153.
21. Salaszyk RM, Klees RF, Williams WA, Boskey A, Plopper GE. Focal adhesion kinase signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells. *Exp Cell Res* 2007; **313**: 22–37.
22. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. *Science* 1997; **276**: 1425–1428.
23. Nho RS, Xia H, Kahm J, Kleidon J, Diebold D, Henke CA. Role of integrin-linked kinase in regulating phosphorylation of Akt and fibroblast survival in type I collagen matrices through a beta1 integrin viability signaling pathway. *J Biol Chem* 2005; **280**: 26630–26639.
24. Tiberio R, Marconi A, Fila C, Fumelli C, Pignatti M, Krajewski S *et al*. Keratinocytes enriched for stem cells are protected from anoikis via an integrin signaling pathway in a Bcl-2 dependent manner. *FEBS Lett* 2002; **524**: 139–144.
25. Ruhl M, Sahin E, Johannsen M, Somasundaram R, Manski D, Riecken EO *et al*. Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. *J Biol Chem* 1999; **274**: 34361–34368.
26. Song SW, Chang W, Song BW, Song H, Lim S, Kim HJ *et al*. Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. *Stem Cells* 2009; **27**: 1358–1365.
27. Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM. The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. *Am J Pathol* 2002; **161**: 337–344.
28. Gardner H, Kreidberg J, Koteliensky V, Jaenisch R. Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. *Dev Biol* 1996; **175**: 301–313.
29. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S *et al*. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. *Hum Mutat* 2007; **28**: 209–221.
30. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP *et al*. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. *J Clin Invest* 2001; **107**: 899–907.
31. Rodriguez JP, Montecinos L, Rios S, Reyes P, Martinez J. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. *J Cell Biochem* 2000; **79**: 557–565.
32. Perinpanayagam H, Zaharias R, Stanford C, Brand R, Keller J, Schneider G. Early cell adhesion events differ between osteoporotic and non-osteoporotic osteoblasts. *J Orthop Res* 2001; **19**: 993–1000.
33. Stenderup K, Justesen J, Eriksen EF, Rattan SI, Kassem M. Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis. *J Bone Miner Res* 2001; **16**: 1120–1129.
34. Bellantuono I, Aldahmash A, Kassem M. Aging of marrow stromal (skeletal) stem cells and their contribution to age-related bone loss. *Biochim Biophys Acta* 2009; **1792**: 364–370.
35. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D *et al*. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315–317.
36. Croitoru-Lamoury J, Lamoury FM, Zaunders JJ, Veas LA, Brew BJ. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. *J Interferon Cytokine Res* 2007; **27**: 53–64.
37. Velling T, Kusche-Gullberg M, Sejersen T, Gullberg D. cDNA cloning and chromosomal localization of human alpha(11) integrin. A collagen-binding, I domain-containing, beta(1)-associated integrin alpha-chain present in muscle tissues. *J Biol Chem* 1999; **274**: 25735–25742.
38. Kennea NL, Stratou C, Naparus A, Fisk NM, Mehmet H. Functional intrinsic and extrinsic apoptotic pathways in human fetal mesenchymal stem cells. *Cell Death Differ* 2005; **12**: 1439–1441.
39. Docheva D, Padula D, Popov C, Mutschler W, Clausen-Schaumann H, Schieker M. Researching into the cellular shape, volume and elasticity of mesenchymal stem cells, osteoblasts and osteosarcoma cells by atomic force microscopy. *J Cell Mol Med* 2008; **12**: 537–552.
40. Böker W, Yin Z, Drosse I, Haasters F, Rossmann O, Wierer M *et al*. Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. *J Cell Mol Med* 2008; **12**: 1347–1359.



**Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>**

Supplementary Information accompanies the paper on Cell Death and Disease website (<http://www.nature.com/cddis>)